Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1652-1661

  Puchalski, Thomas ^a   Prabhakar, Uma ^a   Jiao, Qun ^a   Berns, Birge ^b   Davis, Hugh M ^a  

^a Centocor Research and Development Inc   (United States)

^b Janssen Research and Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; CHIMERIC ANTIBODY; CNTO 328; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SILTUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; COMPUTER SIMULATION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 77649172209     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2581     Document Type: Article

References (21)

1. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 2007; 110:1911-28.
2. Goswami S, Gupta A, Sharma SK. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 1998;71:1837-45.
3. Mauray S, Fuzzati-Armentero MT, Trouillet P, et al. Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 2000;30:2065-73.
4. Weissglas M, Schamhart D, Lowik C, Papapoulos S, Vos P, Kurth KH. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 1995;153:854-7.
5. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001;48:47-53.
6. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
7. Fumagalli L, Lissoni P, Di Felice G, et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 1999; 80:407-11.
8. Pelliniemi TT, Irjala K, Mattila K, et al, Finnish Leukemia Group. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995;85:765-71.
9. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
10. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
11. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-8.
12. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-204.
13. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
14. Emilie D, Wijdenes J, Gisselbrecht C, et al. Administration of an antiinterleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 1994;84:2472-9.
15. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995;86: 3123-31.
16. van Zaanen HC, Koopmans RP, Aarden LA, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996;98:1441-8.
17. van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric antiinterleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-90.
18. Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine 1993;5:578-82.
19. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
20. Mauger JF, Levesque J, Paradis ME, et al. Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. J Clin Endocrinol Metab 2008;93:3158-64.
21. Foglar C, Lindsey RW. C-reactive protein in orthopedics. Orthopedics 1998;21:687-91.